Point72 Asset Management
NRXP icon

Point72 Asset Management’s NRX Pharmaceuticals NRXP Stock Holding History

Point72 Asset Management’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,979
Closed -$43.3K – 4260
2025
Q4 		$43.3K Buy
+15,979
New +$42.9K ﹤0.01% 3794

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Point72 Asset Management's NRXP Position: Q1 2026 in Review

Point72 Asset Management sold out of NRX Pharmaceuticals (NRXP) in Q1 2026, closing a stake of 15,979 shares — an estimated $43.3K sold.

Point72 Asset Management first reported a position in NRXP in Q4 2025 and held it in 1 quarter. The position peaked at $43.3K in Q4 2025. 33 funds tracked by Wall St. Rank hold NRXP as of Q1 2026.

  • Point72 Asset Management reported no remaining NRX Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 15,979 NRX Pharmaceuticals shares in Q1 2026, an estimated $43.3K.
  • Point72 Asset Management first reported a position in NRX Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Point72 Asset Management's NRX Pharmaceuticals position peaked at $43.3K in Q4 2025.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.